April 2018 Volume 14, Issue 4

Volume 14, Issue 4 | April 2018

April 2018

In this Issue

Editor's Focus

Drug Discovery News Placeholder Image

NIH needs more, not less

Can we please stop talking about cutting the National Institutes of Health budget; it's just about one of the last things we need right now (or ever)

Research & Development

Drug Discovery News Placeholder Image

Cellular chariots

TSRI researchers link cellular cargo transport machinery to neurological disorders
Drug Discovery News Placeholder Image

Oral peptide availability at last?

TUM team details a method for designing peptide agents with oral availability and intestinal permeability
Drug Discovery News Placeholder Image

Patient-on-a-Chip progresses

Organ-on-a-chip tech recreates human intestinal lining; program launched to test chips in treatment selection
Drug Discovery News Placeholder Image

Sulfones at Scripps

A new cross-coupling simplifies the synthesis of drug-like molecules
Drug Discovery News Placeholder Image

All about antibodies

Merger marries cutting-edge research players

Preclinical

Drug Discovery News Placeholder Image

The truth about TREM2

Brain’s immune system may be key to new Alzheimer’s treatments
Drug Discovery News Placeholder Image

Organogold antibiotics

Auspherix gets Innovate UK grant to explore therapeutic for difficult infections
Drug Discovery News Placeholder Image

Obsidian advances destabilizing domains

Company presents data demonstrating its CAR-T platform for safer, more effective cancer treatments
Drug Discovery News Placeholder Image

Targeting TGFβ

Research team identifies a hormone that prevents colon cancer from responding to immunotherapy
Drug Discovery News Placeholder Image

Argos obtains option to license PD1 checkpoint inhibitors

Data have shown synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in preclinical renal carcinoma model

Special Reports

Drug Discovery News Placeholder Image

Special Report on Neuroscience: Beyond ‘reefer madness’

Companies and academic researchers work to convert Cannabis self-pharmacy to science

Feature

Drug Discovery News Placeholder Image

Show Preview: Immunology 2018--Austin-bound for immunology

American Association of Immunologists brings annual meeting to Texas

Contract Services

Drug Discovery News Placeholder Image

CAR-T manufacturing potential moves to Asia

With half of CAR-T studies in China, Cesca looks to capitalize on market potential with CDMO expansion
Drug Discovery News Placeholder Image

Speeding the flow with downstream conjugation

ADC Bio introduces new method for antibody-drug conjugate manufacture
Drug Discovery News Placeholder Image

HemaCare and Charles River aim to accelerate drug discovery and development

PBMC humanization kits for NCG mouse models are said to facilitate infectious disease and immuno-oncology research

Diagnostics

Drug Discovery News Placeholder Image

Faster pathway through proteomics?

A recently completed study supports the value of multiplexed mass spectrometry tests for diagnosing lung cancer and pre-term births
Drug Discovery News Placeholder Image

Xpresys Lung 2 lances lung cancer

Test identifies benign lung nodules with high probability to avoid unnecessary invasive procedures
Drug Discovery News Placeholder Image

Advancing cancer immunotherapy

Personal Genome Diagnostics expands its tumor mutational burden patent portfolio
Drug Discovery News Placeholder Image

Telix and Radboud seal clinical collaboration agreement

Work will focus on several clinical projects in relation to imaging diagnostics for cancer

Discovery

Drug Discovery News Placeholder Image

Linking up for bacteria libraries

Deinove granted access to Naicons’ bacterial strain library in search of new antibiotics
Drug Discovery News Placeholder Image

Stem cell promise for kidney disease

CD133 revealed as a potential target for encouraging kidney repair
Drug Discovery News Placeholder Image

Companies join forces in screening solution technology

Genedata, HighRes Bio and Titian smooth the way from beginning to end
Drug Discovery News Placeholder Image

Glutamate and its role in addiction

Indiana University-led study finds neurotransmitter glutamate may play a role in alcohol relapse, addiction

Business & Government Policy

Drug Discovery News Placeholder Image

V ClinBio forges clear path to FDA

Acquires equity stake in Cellix Bio and its Synergix drug delivery program; partners with Camargo
Drug Discovery News Placeholder Image

On the cutting edge

A roundup of instrumentation, software and other tools and technology news
Drug Discovery News Placeholder Image

Advancing from the acquisition

RNA hybridization, multiplex assays central to Bio-Techne’s growth plans in wake of acquiring Advanced Cell Diagnostics
Drug Discovery News Placeholder Image

It’s all in the delivery

Checking out the news in drug delivery advancements
Drug Discovery News Placeholder Image

NIH completes in-depth genomic analysis of 33 cancer types

Researchers funded by the National Institutes of Health have completed a detailed genomic analysis, known as the PanCancer Atlas

Clinical Trials

Curing HBV for good

Spring Bank takes combinatorial approach to hepatitis B virus
Drug Discovery News Placeholder Image

Informa teams up with Saama on trials

Aim is to leverage AI to offer customers a complete understanding of the clinical trial landscape
Drug Discovery News Placeholder Image

A new weapon in the opioid struggle

Opiant announces development of intranasal nalmefene for treatment of opioid overdose
Drug Discovery News Placeholder Image

Reducing cancer recurrence with BPX-501

Bellicum reports encouraging results in pediatric patients with primary immunodeficiencies

Commentary

Drug Discovery News Placeholder Image

Theranos: Lessons learned

A company that makes too many promises it cannot keep and doesn't even surround itself with scientific experts probably shouldn't be in the life-sciences business
Drug Discovery News Placeholder Image

Guest Commentary: Preclinical studies gain the edge with syngeneic models

Syngeneic mouse models are employed extensively in early-stage drug discovery and have become a workhorse for one of the fastest-growing areas of research, immuno-oncology, transforming how investigators approach novel therapies

Q&A

Drug Discovery News Placeholder Image

Q&A: Pharnext and Pleotherapy

French biopharma addresses neurodegenerative diseases, combining low doses of existing drugs to develop treatments for new indications using big data analysis
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue